
CITATION REPORT List of articles citing



DOI: 10.2174/138161209789206971 Current Pharmaceutical Design, 2009, 15, 3464-75.

Source: https://exaly.com/paper-pdf/45614292/citation-report.pdf

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
58	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. <i>Pharmacological Reviews</i> , 2010 , 62, 525-63	22.5	677
57	Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. <i>Gastrointestinal Endoscopy</i> , 2011 , 74, 556-62	5.2	11
56	Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia. <i>Pregnancy Hypertension</i> , 2011 , 1, 231-7	2.6	5
55	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. <i>Pharmacological Reviews</i> , 2011 , 63, 811-59	22.5	213
54	Dynamic observation of penile hemodynamic change in patients with vasculogenic erectile dysfunction after prostaglandin E1 treatment. <i>Scientific Research and Essays</i> , 2011 , 6, 3770-3775	0.7	
53	Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. <i>Andrologia</i> , 2011 , 43, 208-12	2.4	7
52	Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3418-32	1.1	71
51	Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , 2011 , 60, 380-7	10.2	46
50	High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. <i>Journal of Chromatography A</i> , 2011 , 1218, 7996-8001	4.5	20
49	Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). Expert Opinion on Therapeutic Patents, 2011 , 21, 1631-41	6.8	19
48	Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 10540-50	8.3	24
47	The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 498-509	3.4	16
46	ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. <i>Trials</i> , 2013 , 14, 188	2.8	7
45	A one-pot, three-component, microwave-promoted synthesis of 2-amino-substituted 7-amino-1,2,4-triazolo[1,5-a][1,3,5]triazines. <i>Tetrahedron Letters</i> , 2013 , 54, 5537-5540	2	21
44	Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study. <i>Andrology</i> , 2013 , 1, 549-55	4.2	8
43	Tadalafil-induced tonic-clonic seizures in a 23-year-old man. <i>Epilepsy and Behavior</i> , 2013 , 28, 519-20	3.2	7
42	Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 705-17	6.9	17

41	Erectile dysfunction. Lancet, The, 2013, 381, 153-65	40	545
40	The selectivity and potency of the new PDE5 inhibitor TPN729MA. <i>Journal of Sexual Medicine</i> , 2013 , 10, 2790-7	1.1	13
39	Udenafil: efficacy and tolerability in the management of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2013 , 5, 101-10	3.2	14
38	DISCOVERY AND DEVELOPMENT OF ISOZYME-SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM. 2013 , 55-80		
37	. 2013,		
36	Udenafil for the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 341-54	2.9	16
35	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 53-64	2.6	17
34	Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: a case study of PDE5 and its inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 3588-93	8.3	28
33	PnPP-19, a Synthetic and Nontoxic Peptide Designed from a Phoneutria nigriventer Toxin, Potentiates Erectile Function via NO/cGMP. <i>Journal of Urology</i> , 2015 , 194, 1481-90	2.5	29
32	PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. <i>American Heart Journal</i> , 2015 , 169, 813-822.e3	4.9	31
31	Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 4970906	6.7	5
30	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 141-52	4.1	35
29	The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. <i>Renal Failure</i> , 2016 , 38, 357-61	2.9	2
28	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 6622-6637	8.3	23
27	Medical treatment of erectile dysfunction: too many medical prescriptions?. <i>Urologia</i> , 2017 , 84, 121-129	9 1.2	3
26	Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats. <i>African Journal of Pharmacy and Pharmacology</i> , 2017 , 11, 385-393	0.5	3
25	An immunohistochemical and ultrastructural analysis of the retina in tadalafil (Cialis) treated rats. <i>Acta Histochemica</i> , 2018 , 120, 312-322	2	1
24	Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 905-912	2.9	5

23	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 151, 91-105	3.5	1
22	The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018 , 96, 1308-1317	2.4	20
21	Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. Ecancermedicalscience, 2018 , 12, 824	2.7	24
20	Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New?. <i>Current Hypertension Reports</i> , 2018 , 20, 83	4.7	5
19	A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation. <i>Biomolecules</i> , 2019 , 9,	5.9	8
18	Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure. <i>Drugs and Aging</i> , 2019 , 36, 991-997	4.7	3
17	Ocular Effects of Sildenafil in NaWe Mice and a Mouse Model of Optic Nerve Crush. 2019 , 60, 1987-1995		4
16	PnPP-19 Peptide Restores Erectile Function in Hypertensive and Diabetic Animals Through Intravenous and Topical Administration. <i>Journal of Sexual Medicine</i> , 2019 , 16, 365-374	1.1	5
15	Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. <i>European Neuropsychopharmacology</i> , 2020 , 30, 17-29	1.2	8
14	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. British Journal of Pharmacology, 2020 , 177, 5467-5488	8.6	34
13	Dopamine D1 Receptor in Cancers. Cancers, 2020, 12,	6.6	7
12	Monitor recipients of phosphodiesterase type 5 inhibitors for glaucoma, pending more clinical evidence of risk. <i>Drugs and Therapy Perspectives</i> , 2020 , 36, 152-155	1.5	
11	Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review. <i>Journal of Ethnopharmacology</i> , 2021 , 267, 113536	5	7
10	Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B. <i>Research Results in Pharmacology</i> , 2021 , 7, 1-19	0.5	
9	Sildenafil in Combination Therapy against Cancer: A Literature Review. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2248-2259	4.3	3
8	When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex". <i>Current Neuropharmacology</i> , 2017 , 15, 762-770	7.6	85
7	Effect of Udenafil on MUC5B Expression in Human Airway Epithelial Cells. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2013 , 56, 501	0.2	8
6	Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1 <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019 , 2, 933-947	4.5	О

CITATION REPORT

5	Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. <i>Molecular and Cellular Pharmacology</i> , 2010 , 2, 173-178		17
4	A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction <i>Sexual Medicine Reviews</i> , 2022 ,	5.6	1
3	Efficacy and Safety of Udenafil Once Daily in Patients with Erectile Dysfunction after Bilateral Nerve-Sparing Robot-Assisted Laparoscopic Radical Prostatectomy: A Randomized, Double-Blind, Placebo-Controlled Study. 40,		1
2	The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation. 2022 ,		О
1	A label-free LC/MS-based enzymatic activity assay for the detection of PDE5A inhibitors. 11,		0